Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9621908 | 0.76 | MEN1 (0.46) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL7106896 | 0.75 | KDM4E (0.42) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL7108620 | 0.71 | CA1 (0.36) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL7109900 | 0.70 | CA1 (0.38) | KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL9353851 | 0.67 | PADI4 (0.44) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL30226928 | 0.67 | TYMS (0.35) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL7108615 | 0.66 | CYP2A6 (0.48) | KDM4EALDH1A1MAPTHSD17B10POLB | |
| SCHEMBL14957507 | 0.65 | MAPT (0.41) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL10866066 | 0.65 | PKM (0.41) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL11854817 | 0.63 | KMT2A (0.38) | MEN1KMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458993-B1 | AROMATIC CYANATE ESTER COMPOUNDS HAVING AT LEAST TWO RINGS LINKED BY AN UNSATURATED GROUP CONTAINING MEMBER CAN BE EMPLOYED IN ADHESIVES, COMPOSITES, LAMINATES AND MOLDINGS | VANTICO INC. | 2002-10-01 | — | — | US | claimed |
| US-20020055648-A1 | Cyanate esters having flame resistant properties | JPMORGAN CHASE BANK, N.A. | 2002-05-09 | — | — | US | claimed |
| EP-1161414-B1 | CYANATE ESTERS HAVING FLAME RESISTANT PROPERTIES | VANTICO AG (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6458993-B1 | AROMATIC CYANATE ESTER COMPOUNDS HAVING AT LEAST TWO RINGS LINKED BY AN UNSATURATED GROUP CONTAINING MEMBER CAN BE EMPLOYED IN ADHESIVES, COMPOSITES, LAMINATES AND MOLDINGS | VANTICO INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020055648-A1 | Cyanate esters having flame resistant properties | JPMORGAN CHASE BANK, N.A. | 2002-05-09 | — | — | US | disclosed |
| EP-1161414-A1 | CYANATE ESTERS HAVING FLAME RESISTANT PROPERTIES | Vantico AG (CH) | 2001-12-12 | — | — | EP | disclosed |
| US-6242638-B1 | FIREPROOFING USING CURED MIXTURES | VANTICO INC. | 2001-06-05 | — | — | US | disclosed |
| WO-2000055123-A1 | CYANATE ESTERS HAVING FLAME RESISTANT PROPERTIES | VANTICO AG (CH) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055648-A1 | Cyanate esters having flame resistant properties | PCCA, FABP4, MCCC2 | MEN1 3837/4885KMT2A 1378/4885KDM4E 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.